Lauren Williamson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren Williamson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- John P. Jones Iii
WPLab, USA
6 shared publications - William Parker
Surgery Durham NC 27710 Duke University Medical Center
6 shared publications - Zacharoula Konsoula
WPLab, USA
6 shared publications - Rachel Anderson
WPLab, USA
5 shared publications - Kathryn J. Reissner
Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 shared publications - Susanne Meza-Keuthen
WPLab, USA
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by MDPI AG in Preprints.org
Considering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- 7 September 2026
- Published by MDPI AG in Preprints.org
Open AccessConsidering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
An Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessAn Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- Open Access
- 1 August 2025
- Published by MDPI AG in Preprints.org
Evidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade
Overwhelming evidence shows that exposure of susceptible babies and children to acetaminophen (paracetamol) triggers many if not most cases of autism spectrum disorder, and that oxidative stress causes susceptibility. However, these conclusions have not yet been widely acknowledged or integrated into clinical practice or regulatory guidelines, leaving the continued high prevalence of autism spectrum disorder unchecked. To understand why the conclusions have not been widely accepted, this study conducts systematic analyses of all PubMed-indexed papers with “acetaminophen” and “autism” in any search field. In these papers, statements that failed to promote changes in clinical practice or regulatory guidelines were pervasive. Also pervasive were mishandlings of available evidence, including treating interacting variables as if they are confounding factors (66% of studies affected) and considering too narrow a range of evidence (77% of studies affected). Also present were erroneous criticisms of potentially groundbreaking research, undermining the potential impact of that research. It is hoped that identification of these fundamental problems will lead to widespread acceptance of the evidence that acetaminophen triggers autism spectrum disorder in susceptible babies and children and to subsequent regulatory and clinical changes that will effectively and quickly reduce the induction of autism spectrum disorder.
- 1 August 2025
- Published by MDPI AG in Preprints.org
Open AccessEvidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade
Overwhelming evidence shows that exposure of susceptible babies and children to acetaminophen (paracetamol) triggers many if not most cases of autism spectrum disorder, and that oxidative stress causes susceptibility. However, these conclusions have not yet been widely acknowledged or integrated into clinical practice or regulatory guidelines, leaving the continued high prevalence of autism spectrum disorder unchecked. To understand why the conclusions have not been widely accepted, this study conducts systematic analyses of all PubMed-indexed papers with “acetaminophen” and “autism” in any search field. In these papers, statements that failed to promote changes in clinical practice or regulatory guidelines were pervasive. Also pervasive were mishandlings of available evidence, including treating interacting variables as if they are confounding factors (66% of studies affected) and considering too narrow a range of evidence (77% of studies affected). Also present were erroneous criticisms of potentially groundbreaking research, undermining the potential impact of that research. It is hoped that identification of these fundamental problems will lead to widespread acceptance of the evidence that acetaminophen triggers autism spectrum disorder in susceptible babies and children and to subsequent regulatory and clinical changes that will effectively and quickly reduce the induction of autism spectrum disorder.
- Open Access
Evaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism Spectrum Disorder
More than 20 previously reported lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to the aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in silico methods to create an ideal (virtual) population of 120,000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal dataset shows little to no risk of acetaminophen use if the cofactors that create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors that impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in the analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
Open AccessEvaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism Spectrum Disorder
More than 20 previously reported lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to the aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in silico methods to create an ideal (virtual) population of 120,000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal dataset shows little to no risk of acetaminophen use if the cofactors that create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors that impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in the analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
- Open Access
- 4 June 2024
- Published by MDPI AG in Preprints.org
Evaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism
More than 20 lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations previously indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in-silico methods to create an ideal (virtual) population of 120000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal data set shows little to no risk of acetaminophen use if cofactors which create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors which impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
- 4 June 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism
More than 20 lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations previously indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in-silico methods to create an ideal (virtual) population of 120000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal data set shows little to no risk of acetaminophen use if cofactors which create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors which impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
- Open Access
The Dangers of Acetaminophen for Neurodevelopment Outweigh Scant Evidence for Long-Term Benefits
Based on available data that include approximately 20 lines of evidence from studies in laboratory animal models, observations in humans, correlations in time, and pharmacological/toxicological considerations, it has been concluded without reasonable doubt and with no evidence to the contrary that exposure of susceptible babies and children to acetaminophen (paracetamol) induces many, if not most, cases of autism spectrum disorder (ASD). However, the relative number of cases of ASD that might be induced by acetaminophen has not yet been estimated. Here, we examine a variety of evidence, including the acetaminophen-induced reduction of social awareness in adults, the prevalence of ASD through time, and crude estimates of the relative number of ASD cases induced by acetaminophen during various periods of neurodevelopment. We conclude that the very early postpartum period poses the greatest risk for acetaminophen-induced ASD, and that nearly ubiquitous use of acetaminophen during early development could conceivably be responsible for the induction in the vast majority, perhaps 90% or more, of all cases of ASD. Despite over a decade of accumulating evidence that acetaminophen is harmful for neurodevelopment, numerous studies demonstrate that acetaminophen is frequently administered to children in excess of currently approved amounts and under conditions in which it provides no benefit. Further, studies have failed to demonstrate long-term benefits of acetaminophen for the pediatric population, leaving no valid rationale for continued use of the drug in that population given its risks to neurodevelopment.
Open AccessThe Dangers of Acetaminophen for Neurodevelopment Outweigh Scant Evidence for Long-Term Benefits
Based on available data that include approximately 20 lines of evidence from studies in laboratory animal models, observations in humans, correlations in time, and pharmacological/toxicological considerations, it has been concluded without reasonable doubt and with no evidence to the contrary that exposure of susceptible babies and children to acetaminophen (paracetamol) induces many, if not most, cases of autism spectrum disorder (ASD). However, the relative number of cases of ASD that might be induced by acetaminophen has not yet been estimated. Here, we examine a variety of evidence, including the acetaminophen-induced reduction of social awareness in adults, the prevalence of ASD through time, and crude estimates of the relative number of ASD cases induced by acetaminophen during various periods of neurodevelopment. We conclude that the very early postpartum period poses the greatest risk for acetaminophen-induced ASD, and that nearly ubiquitous use of acetaminophen during early development could conceivably be responsible for the induction in the vast majority, perhaps 90% or more, of all cases of ASD. Despite over a decade of accumulating evidence that acetaminophen is harmful for neurodevelopment, numerous studies demonstrate that acetaminophen is frequently administered to children in excess of currently approved amounts and under conditions in which it provides no benefit. Further, studies have failed to demonstrate long-term benefits of acetaminophen for the pediatric population, leaving no valid rationale for continued use of the drug in that population given its risks to neurodevelopment.